|
PERSONALIZE:
Overlook
at Great Notch
150 Clove Road
Little Falls,
New Jersey 07424
Telephone:
(973) 890-8988
Fax:
(973) 890-8866
|
|
Tx Reporter Series |
This activity has reached its termination date and no longer offers continuing education credit.
Tx Reporter Series
The primary cause of anemia in patients with hemodialysis-dependent chronic kidney disease (HD-CKD) is impaired production of endogenous erythropoietin by the kidneys. Erythropoiesis-stimulating agents (ESAs), first introduced in 1989, represent an opportunity to correct anemia in HD-CKD. In the vast majority of HD-CKD patients, ESA use increases hemoglobin to target levels, affording significant quality of life benefits. However, not all patients respond readily to ESA therapy.
We hope you find this series helpful and informative, and that the discussions will assist you in incorporating this information into your clinical practice. |
|
